Acadia Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Acadia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company's commercial portfolio is anchored by two key franchises: its neurological disease franchise, led by NUPLAZID (pimavanserin)—the first and only FDA-approved drug for hallucinations and delusions associated with Parkinson's disease psychosis (PDP)—and its rare disease franchise, led by DAYBUE (trofinetide), the first and only FDA-approved treatment for Rett syndrome. Acadia is also advancing a robust clinical pipeline targeting other underserved neurological and neuro-rare indications, including remlifanserin (ACP-204) for Alzheimer's disease psychosis and ACP-711 for essential tremor.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Full commercial launch of DAYBUE STIX (trofinetide) oral solution powder formulation in the United States, targeting patients who discontinued or declined the liquid formulation.
Expected impact: Aims to capture treatment-naive patients and return previous discontinuers, driving DAYBUE net sales toward the guided $460 million to $490 million range for 2026.
Expanding the reach of trofinetide (DAYBUE) outside the United States through regulatory filings and distribution partnerships.
Expected impact: Securing international approvals and establishing named patient programs to generate new revenue streams outside North America.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Globally manages Named Patient Supply of DAYBUE (trofinetide) in specific emerging markets, primarily in Asia-Pacific (ex-Japan), South Asia, Latin America, the Middle East, North Africa, and South Africa.
Terms: Terms not fully disclosed; FarmaMondo acts as the exclusive distributor to manage supply and access.
Acadia holds exclusive global development and commercialization rights to trofinetide (DAYBUE) for Rett syndrome.
Terms: Acadia pays royalties on net sales of DAYBUE to Neuren (e.g., Neuren expects 2026 royalty income of A$70 million to A$77 million based on Acadia's sales guidance).